BACKGROUND: Forty-five percent of births in the United States are unintended, and the costs of unintended pregnancy and birth are substantial. Clinical and policy interventions that increase access to the most effective reversible contraceptive methods (intrauterine devices and contraceptive implants) have potential to generate significant cost savings. Evidence of cost savings for these interventions is needed. OBJECTIVE: The purpose of this study was to conduct a cost-savings analysis of the Contraceptive CHOICE Project, which provided counseling and no-cost contraception, to demonstrate the value of investment in enhanced contraceptive care to the Missouri Medicaid program. STUDY DESIGN: The Contraceptive CHOICE Project was a prospective cohort study of 9256 reproductive-age women who were enrolled between 2007 and 2011. Study follow-up was completed October 2013. This analysis includes 5061 Contraceptive CHOICE Project participants who were current Missouri Medicaid beneficiaries or were uninsured and reported household incomes <201% of the federal poverty line. We created a simulated comparison group of women who were receiving care through the Missouri Title X program and modeled the contraception and pregnancy outcomes that would have occurred in the absence of the Contraceptive CHOICE Project. Data about contraceptive use for the comparison group (N¼5061) were obtained from the Missouri Title X program and adjusted based on age, race, ethnicity, and income. To make an accurate comparison that would account for the difference in the 2 populations, we used our simulation model to estimate total Contraceptive CHOICE Project costs and total comparison group costs. We reported all costs in 2013 dollars to account for inflation. RESULTS: Among the Contraceptive CHOICE Project participants who were included, the uptake of intrauterine devices and implants was 76.1% compared with 4.8% among the comparison group. The estimated contraceptive cost for the simulated Contraceptive CHOICE Project group was $4.0 million vs $2.3 million for the comparison group. The estimated numbers of unintended pregnancies and births averted among the simulated Contraceptive CHOICE Project group compared with the comparison group were 927 and 483, respectively, which represented a savings in pregnancy and maternity care of $6.7 million. We estimated that the total cost savings for the state of Missouri attributable to the Contraceptive CHOICE Project was $5.0 million (40.7%) over the project duration. CONCLUSION: A program providing counseling and no-cost contraception yields substantial cost savings because of the increased uptake of highly effective contraception and consequent averted unintended pregnancy and birth.
U nintended pregnancy carries significant public health costs that include reduced maternal quality of life, adverse maternal behaviors, and poorer infant outcomes. 1, 2 Societal costs are also large and include reduced educational attainment, employment opportunities, economic stability, and greater dependence on public assistance. 3 The economic costs of unintended pregnancy and birth are substantial, and US taxpayers pay roughly $11 billion each year in costs that are associated with unintended pregnancy. 4 The Contraceptive CHOICE Project was a prospective study of 9256 reproductive-age women that provided comprehensive contraceptive counseling, no-cost contraception, and reduced barriers to reversible contraception. These barriers included provider misconceptions, 5 high outof-pocket cost, 6 and multiple visit requirements for initiation of long-acting reversible contraception (LARC: intrauterine devices [IUDs] and implants). 7, 8 Contraceptive CHOICE Project participants had a high uptake of LARC and subsequent reductions in unintended and teen pregnancy. 9, 10 Multiple studies have demonstrated that the provision of contraception, which includes LARC, results in economic savings. 11, 12 One cost-effectiveness analysis found that, although LARC is associated with higher upfront costs, these methods generate cost savings after approximately 2 years of use. 13 The objective of this analysis was to estimate the cost savings that the Contraceptive CHOICE Project contributed to the Missouri Medicaid program over the study period. Our secondary objective was to estimate potential public cost savings if the Contraceptive CHOICE Project model were scaled up to Missouri Medicaid beneficiaries statewide.
Materials and Methods

Model design and population
Participants in the Contraceptive CHOICE Project were enrolled between 2007 and 2011 and followed for 2 or 3 years through October 2013. 14 Inclusion criteria for the Contraceptive CHOICE Project included age 14e45 years, not currently using a reversible contraceptive method or willing to start a new method, did not desire pregnancy for the next 12 months, sexually active with a male partner, and resided in the St. Louis area. We limited inclusion in this analysis to Original Research ajog.org women who reported receipt of Medicaid or had incomes <201% of the federal poverty level, which is the income eligibility threshold for Missouri's family planning waiver program, the Missouri Women's Health Services Program (MO-WHSP), and pregnancy-related Medicaid. The time horizon for the analysis was 45 months, which included the 36-month study period plus an additional 9 months to account for any births that resulted from conception that occurred during the study period.
To create a comparison group for the analysis, we estimated the contraceptive method distribution that women would have selected in the absence of the Contraceptive CHOICE Project. We used data regarding the contraceptive method chosen by women who received care at Missouri health centers that participated in the Title X program between 2008 and 2012. Women who were currently pregnant, seeking pregnancy, or had a previous sterilization were excluded, as they were excluded from the Contraceptive CHOICE Project. Given the demographic differences between the Contraceptive CHOICE Project cohort and the Title X program participants (Table 1) , we used multinomial logistic regression to obtain probabilities that a Contraceptive CHOICE Project participant, in the absence of the study intervention, would have selected each method. Contraceptive outcomes were categorized in the following manner: (1) IUD or implant; (2) injectable contraception; (3) oral contraceptive pills (OCPs), contraceptive patch, or vaginal ring; (4) condoms, other barriers methods, withdrawal, or fertility awareness; and (5) no method. Adjustment was limited to 4 demographic characteristics because of the available Missouri Title X data: age (19, 20e29 , and 30 years old), race (white, black, and other race), Hispanic identity (non-Hispanic and Hispanic), and federal poverty level (<101% of the federal poverty level and 101e200% of the federal poverty level). This group formed the basis for a counterfactual simulation of the actual Contraceptive CHOICE Project participants' experience in the absence of the Contraceptive CHOICE Project, thereby creating a comparison group with the Contraceptive CHOICE Project participant demographics but whose contraceptive choices were based on the Missouri Title X population.
For each woman in the comparison group, we conducted a Monte Carlo simulation of outcomes and associated costs by executing 1000 draws from the contraceptive distribution given by evaluating the multinomial logistic regression equation using the Contraceptive CHOICE Project participants' specific demographic profiles. For each draw, we simulated the month-to-month occurrence of pregnancy and all possible outcomes (using assumptions discussed in detail later) and tallied associated costs, averaged over 1000 draws to smooth cost estimates. This generated 2 sets of simulated results: (1) those for the Contraceptive CHOICE Project population as predicted by our simulation and (2) those for the comparison group. The simulated results for the Contraceptive CHOICE Project helped to test the accuracy and reasonableness of the assumptions entered into the simulation. All analyses were performed in SAS software (version 9.4; SAS Institute, Cary, NC) and STATA software (version 14; StataCorp, College Station, TX).
Use of contraceptive methods
For Contraceptive CHOICE Project participants, the assigned contraceptive method was the method chosen by the participant at study enrollment. For the comparison group, the method was assigned probabilistically using the Missouri Title X health center data described earlier. Methods were grouped into the same 5 contraceptive categories described earlier. To account for contraceptive discontinuation among women who chose an IUD or implant at baseline, we used published Contraceptive CHOICE Project continuation rates at 1 and 2 years using a linear trend to estimate monthly continuation rates. 15 In case of discontinuation, we assumed the same contraceptive distribution as the comparison group at baseline.
Costs of contraceptive methods
To estimate the contraceptive costs across both the Contraceptive CHOICE Project and comparison populations, we used Missouri Medicaid reimbursement rates for IUDs, implants, and injectable contraception, and the retail acquisition costs for OCPs, patch, and ring for years 2007 through 2011. These methodspecific costs were incorporated into the simulation each time a particular method was drawn. Sensitivity of our results to these values was assessed by the simulation substituting the annual averaged contraceptive costs estimated by Laliberte et al 16 who used Medicaid claims data for 11 million women across multiple states (including Missouri) between 2004 and 2010. Use of the averaged contraceptive costs showed AJOG at a Glance Why was this study conducted? We conducted this cost-savings analysis to estimate the cost savings to Missouri Medicaid because of the high uptake of intrauterine devices and implants in the Contraceptive CHOICE Project and subsequent unintended pregnancies that were averted.
Key Findings
In this cost-savings analysis of 5061 reproductive-age women who had been provided with no-cost contraception, Missouri Medicaid saved an estimated $5.0 million because of 483 unintended births that were averted.
What does this add to what is known?
These results provide important data about the public cost savings that may result from the increased uptake of intrauterine devices and implants. These data have implications for broader policies aimed at reducing unintended pregnancies and healthcare costs. 
Cost of contraceptive initiation
Because the Contraceptive CHOICE Project involved additional programmatic costs, primarily the provision of evidence-based, comprehensive contraceptive counseling by trained nonclinician counselors, we computed the cost of contraceptive initiation using actual costs from the Contraceptive CHOICE Project. Annual salaries and fringe benefits for a full-time nurse practitioner, a half-time registered nurse, and a full-time contraceptive counselor were averaged over the number of Contraceptive CHOICE Project participants to approximate cost depending on enrollment year. We added 30% to the cost of salaries to account for overhead, such as rent, utilities, and supplies. 17 Because approximately twice the clinician time is required for LARC insertion, the per-participant nurse practitioner cost was calculated as a weighted average, with visits that included LARC insertion weighted twice as much as those for non-LARC methods. For IUDs and implants, method and initiation costs were assumed to occur in year 1 only because the maximum duration of study participation was 3 years; therefore, no method replacement because of expiration was necessary.
Contraceptive initiation costs for the comparison group were estimated with the use of Missouri Medicaid reimbursement rates. The estimated cost of initiation of OCPs, patch, ring, and injectable methods was the reimbursement amount for a new patient level III office visit with a clinician. For initiation costs of IUDs and implants, the reimbursement for a new patient level III visit and the method insertion were summed with the rate weighted by the percent of individuals who chose each type of IUD or the implant. We also calculated Contraceptive CHOICE Project costs using these rates within our simulation to capture the likely cost of a large-scale version of the project. Supplementary Materials Tables 1e3 provide a summary of costs and supporting data sources.
Costs of unintended pregnancyrelated events
To determine the number of unintended pregnancies, we incorporated previously published "typical use" contraceptive failure rates into the simulation model. 18 The simulated Contraceptive CHOICE Project unintended pregnancy and birth outcomes were calibrated to exactly match the actual number of unintended pregnancies and births observed in the Contraceptive CHOICE Project. This calibration occurred within the bounds of parameter ranges suggested by the literature and was chosen deliberately to ensure that the cost calculations would be accurate for the actual Contraceptive CHOICE Project.
Five possible outcomes for unintended pregnancy were considered: live birth, induced abortion covered by Medicaid, induced abortion not covered by Medicaid, miscarriage, and ectopic pregnancy. We used a combination of Contraceptive CHOICE Project data and 2010 estimates for the percentages of unintended pregnancies that result in live birth, miscarriage, or abortion in Missouri. 19 Additional detail is provided in the Supplementary Materials. The percent of pregnancies that ended in an ectopic pregnancy was assumed with the use of the methods described by Trussell et al 13 and subtracted from the miscarriage rate. Most induced abortions were assumed to have zero cost to the state, because Missouri Medicaid does not cover abortion except in cases of maternal life endangerment, rape, and incest. We estimated these events to account for approximately 1% of induced abortions. 20 Based on this fact, we The costs for miscarriage, induced abortions covered by Missouri Medicaid, and ectopic pregnancy were estimated with the use of statistics reported by Trussell et al. 13 All costs were adjusted to 2013 dollars for the final estimates to account for inflation. We did not discount costs because the cost-savings analysis was conducted from a state budgetary perspective and there were minimal changes in Missouri Medicaid reimbursement over the time period.
Scaling up cost savings to approximate savings for the Missouri Medicaid populations
To calculate the cost savings from a statewide "scale-up" of the program, we applied our Contraceptive CHOICE Project simulation model to individual data from the 2009e2013 American Community Survey (ACS), 23 which we limited to all Missouri women 18e45 years old who reported receipt of Medicaid or whose household income and uninsured status made them eligible for the MO-WHSP. This approach provides an estimation of the outcomes in a different population (ie, Missouri women) that is controlled for age, race, ethnicity, and income as described earlier. ACS survey weights were used to scale the savings of Missouri ACS respondents to state population level savings. We used estimates of 20e40% LARC uptake to calculate a possible range of cost savings that might occur in a statewide scale-up.
Results
Estimated contraceptive mix for the Contraceptive CHOICE Project and comparison group Table 2 shows the contraceptive distribution for both groups. Women in the Contraceptive CHOICE Project were more likely to choose an IUD or implant than women in the comparison group, even after the adjustment for baseline demographic differences between the groups. Women in the comparison group were more likely to choose OCPs, injectable contraception, condoms, or no contraceptive method.
Estimated number of unintended pregnancies averted in the Contraceptive CHOICE Project Estimated costs savings resulting from the Contraceptive CHOICE Project for Missouri Medicaid Table 3 also shows the estimated cost savings to Missouri Medicaid because of the Contraceptive CHOICE Project. Not surprisingly, the Contraceptive CHOICE Project was associated with higher contraceptive costs compared with the comparison group, because more women in the Contraceptive CHOICE Project chose IUDs and implants. Most of these costs occurred early in the study period when most women were initiating IUDs and implants as shown in the Figure. The pregnancy-related costs, however, are lower in the Contraceptive CHOICE Project than in the comparison group, both in absolute terms and the annual average, because of the higher number of pregnancies that were averted. Because of the timeline of the Contraceptive CHOICE Project, approximately one-half of the women were observed for 2 rather than 3 years. 15 For this reason, Table 3 reports an overall sum of costs and savings as well as an annualized average that is adjusted to account for the variation in follow-up time. Thus, total costs in the comparison group are estimated to be $12.2 million compared with $7.3 million for the Contraceptive CHOICE Project group, which is a 40.7% reduction in costs that are related to contraception, unintended pregnancy, and birth.
The Figure gives a comparison of monthly costs over time for the simulated Contraceptive CHOICE Project and comparison groups. Higher upfront costs because of the use of IUDs and implants lead to lower costs that occurred during the 2-to 3-year study follow-up period; we extended the comparison 9 months beyond the study end to account for pregnancies that occurred during study participation but the outcome (ie, birth) did not occur until after the study ended, because these costs are also attributable to the study period.
Estimated cost savings scaled up to Missouri Medicaid statewide
ACS data show that 132,058 women of reproductive age received Missouri Medicaid annually. During 2011, the average enrollment in the MO-WHSP was 61,297. 24 A scale-up of the Contraceptive CHOICE Project could save an estimated $79.7 million if 20% of female, reproductive-age, Medicaid beneficiaries chose LARC, which would increase to $156.8 million if 40% chose LARC. The cost savings for the MO-WHSP range from an estimated $29.3 to $75.3 million, respectively for the same rates of LARC uptake. Using ACS data, we also estimated that a total of 123,571 women actually were eligible for the MO-WHSP; if all these eligible women were to enroll, the estimated cost savings for this group would range from $59.0 to $151.9 million (Table 4) .
Comment
In this analysis, we found that the Contraceptive CHOICE Project generated a $5.0 million cost savings for Missouri Medicaid because of unintended births that were averted among women who had Medicaid or who would be eligible for expanded Medicaid in the case of a pregnancy, which represented a 41% reduction in costs for the cohort over the 
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Monthly cost expenditures during the Contraceptive CHOICE Project period. 25, 26 A national study of publicly supported family planning services to 8.9 million women found a $10.5 billion cost savings because of unintended pregnancies that were averted. 27 It is important to note that our cost-savings analysis was conducted for a cohort of 5000 women and estimated only the direct healthcare costs of unintended pregnancies that were averted over the study period, and not associated indirect economic and social costs.
Strengths of this study include the use of a comparison group of Missouri women who sought care at Title X health centers to estimate the contraceptive distribution in the absence of the Contraceptive CHOICE Project. We used the actual unintended pregnancy and birth rates from Contraceptive CHOICE Project to inform the simulation and estimate the number of pregnancies that were averted by the Contraceptive CHOICE Project. The Monte Carlo simulation approach also allowed us to demonstrate the robustness of our findings to a range of assumptions. Last, we were able to obtain Missouri Medicaid level data for the costs of birth and first year of life to create a more precise estimate of costs that were associated with unintended birth, which is the largest contributor to pregnancyrelated costs.
There are some limitations to our study. First, women in both the Contraceptive CHOICE Project and the comparison group were presenting for contraceptive care and therefore may not reflect contraceptive use among the general population. Furthermore, women in the Contraceptive CHOICE Project may have self-selected into the study specifically because they desired LARC and, as result, may not be generalizable to other populations. However, a previous analysis that compared Contraceptive CHOICE Project participants with National Survey of Family Growth and Missouri Behavioral Risk Factor Surveillance System respondents found that, although demographic and contraceptive characteristics did differ, the absolute differences were small. 28 In addition, other programs have demonstrated LARC uptake to be substantially higher than the national estimates. 25, 29, 30 Therefore, it is unlikely that the difference in LARC use between Contraceptive CHOICE Project participants and Missouri Title X patients is attributable mainly to selection bias. In addition, because of limited data for the Missouri Title X patients, we were able to control only for a small number of demographic characteristics, which may influence contraceptive preferences. Last, this analysis did not take into account contraceptive switching or discontinuation for any method other than IUDs and implants. Not capturing the costs that are associated with the initiation of a new method may underestimate contraceptive costs and overestimate the cost savings slightly. We also assumed that women who discontinued an IUD or implant chose a new method based on the distribution of the comparison group. However, women in the Contraceptive CHOICE Project group may have been more likely to choose another IUD or implant, which would underestimate cost savings.
Multiple barriers to LARC continue to exist and include requirements for preauthorization, multiple visits for initiation, insurance access, and cost. 31, 32 Furthermore, the US federal government is working actively to weaken the contraceptive guarantee and the Title X program. 33, 34 However, there are also concerns that the "promotion" of LARC may result in coercive practices. 35, 36 We emphasize that any interventions to increase access to LARC be patientcentered, respect women's autonomy, and include the full range of contraceptive options, while also removing barriers to care.
Our results demonstrate that the increased provision of IUDs and implants can reduce public healthcare spending. The potential cost savings of Sensitivity of our results to specific cost data used was a primary concern. Although we reported our results using actual Contraceptive CHOICE Project costs and Missouri Medicaid reimbursement costs (simulated comparison group), we also ran a version of the model using average Medicaid costs reported in Laliberte et al 1 as an approximation of the mix of reimbursement rates (including contraceptive methods obtained at retail acquisition and public sector pricing) at different health centers. Using these cost data, in which the relative price of LARC compared with OCPs is much lower than in the cost data from the Contraceptive CHOICE Project, we found a total cost for study participants of $11.9 million in the comparison group and $6.3 million in the Contraceptive CHOICE Project case, for a cost savings of $5.6 million (46.7%).
We also calculated Contraceptive CHOICE Project costs on the basis of Medicaid reimbursement rates, instead of the actual program costs that were associated with the staffing required for counseling and contraceptive provision. Using Medicaid reimbursement rates for visit costs, we found a total cost of $12.2 million for study participants and $7.2 million for the comparison group, for a cost savings of $5.0 million (41.2%).
The simulation also relied on a combination of parameter choices that were taken from the literature but adjusted slightly to match the Contraceptive CHOICE Project population. For example, data for Missouri overall show a 64% birth rate from unintended pregnancy, although only 52% of unintended pregnancies among Contraceptive CHOICE Project participants ended in live birth. We experimented with an adjustment method to outcomes for unintended pregnancy that factored in the urban setting of Contraceptive CHOICE Project and found that this could explain approximately one-half of the difference. To do so, we assumed that the state-level abortion rates, reported by Finer and Kost, 2 could be divided into urban and rural rates on a populationweighted basis. We estimated urban and rural populations of women of reproductive age using county-level Census data combined with Urban Influence Codes, 3 which designate counties by urban/rural status. We ran a regression to estimate a parameter that would capture the urban/rural differential and used the result to predict the abortion rate in an urban setting. We thereby estimated that 58% of unintended pregnancies in urban areas of Missouri end in live birth, which approaches, but does not equal, the 52% in the Contraceptive CHOICE Project population. The remaining difference may be due to unobserved characteristics that are specific to the Contraceptive CHOICE Project population, which does pose a limitation to the cost-savings analysis for the Contraceptive CHOICE Project. However, we used the Missouri statewide values for the scaled up analysis.
Finally, to capture data for women who use contraception inconsistently, we assumed that there was non-zero probability each month that a woman would experience a gap in any contraceptive method other than LARC methods. The Guttmacher Institute reports that approximately 23.5% of women who use non-LARC methods have a gap in use while "at risk" of unintended pregnancy and further that women who are at risk for unintended pregnancy experience gaps that average 5 months. 4 The latter statistic includes gaps that occur while the woman is pregnant, so we assumed that the average would be lower for our population that excluded pregnant women. We calibrated our "probability of a gap month" parameter so that the Contraceptive CHOICE Project outcomes would be matched more closely by the simulation model; the chosen value corresponds to an average gap of 0.9 months among women who experience a gap. When scaling up the intervention to all Missouri women who are eligible for Medicaid family planning services and assuming a LARC uptake of 40%, we found that eliminating this probability (that is, making the strong assumption that Missouri women in general experience no gaps while using short-acting contraception) reduces the combined expected savings from $308.6 million to $269.6 million, which is therefore a lower bound for our prediction that assumes a 40% rate of LARC uptake.
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SUPPLEMENTARY The average cost is weighted by the number of women who choose each method per year; c Annual salaries for a full-time nurse practitioner, a half-time registered nurse, and a full-time contraceptive counselor were averaged over the annual number of Contraceptive CHOICE Project enrollees over the study period to approximate costs, depending on the year of enrollment; d Contraceptive initiation costs for the comparison group were estimated with the use of Missouri Medicaid reimbursement rates based on MOHealthNet fee schedule, available at https://apps.dss.mo.gov/fmsFeeSchedules/fsmain. aspx; the estimated cost of initiation of oral contraceptive pills, patch, ring, and injectable contraception was the reimbursement amount for a new patient level III office visit with a clinician; for long-acting reversible contraception initiation costs, a weighted average of the reimbursement for a new visit based on whether each type of intrauterine device or the implant was chosen. 
